2025年11月,一位患有乙型地中海贫血症的英国妇女在接受国民保健体系首次基因编辑治疗(Casgevy)后得到治愈。 A UK woman with beta thalassaemia is cured after receiving the NHS’s first gene-editing therapy, Casgevy, in Nov. 2025.

Kavita Mehta来自英国南部, 一名一个月大时被诊断患有乙型地中海贫血症的女性, 希望她能在2025年11月接受国民保健体系首个基因编辑疗法(Casgevy)后得到治愈。 Kavita Mehta, a woman from southern England diagnosed with beta thalassaemia at one month old, is hopeful she may be cured after receiving the NHS’s first gene-editing therapy, Casgevy, in November 2025. 以CRISPR为基础的治疗恢复了她身体的胎儿血红蛋白生产,使她能够停止常规输血。 The CRISPR-based treatment reactivated her body’s fetal hemoglobin production, allowing her to stop regular blood transfusions. 在化疗和住院6周后,她正在家中恢复,报告能量和福祉有所改善。 After chemotherapy and a six-week hospital stay, she is recovering at home, reporting improved energy and well-being. 医生相信治疗是有效的 如果她一年没有输血 她将被视为已治愈 Doctors believe the therapy is working, and if she remains transfusion-free for a year, she will be considered cured. Mehta在招待中工作,希望治疗能够带来更大的自由,包括旅行和正常生活,她主张更广泛地获得治疗。 Mehta, who works in hospitality, hopes the treatment will enable greater freedom, including travel and a normal life, and she advocates for broader access to the therapy.